MedTrace Logo

Population Pharmacokinetic Model of Amikacin and Vancomycin in Critically Ill Patients

NCT06261164 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2024-02-15

No results posted yet for this study

Summary

The object of the scientific research is the characterization of the pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents.

Conditions

Interventions

DEVICE

Cytosorb® and Oxiris® adsorbents

The pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents.

Sponsors & Collaborators

  • University Clinical Centre of Republic of Srpska

    lead OTHER

Principal Investigators

  • Nikolina Spiric, MPharm · University Clinical Centre of Republic of Srpska

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-31
Primary Completion
2024-12-31
Completion
2025-01-31

Countries

  • Bosnia and Herzegovina

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06261164 on ClinicalTrials.gov